Literature DB >> 1655318

Anti-neutrophil cytoplasm antibodies in rheumatoid arthritis.

J A Savige1, M C Gallicchio, A Stockman, T J Cunningham, M J Rowley, T Georgiou, D Davies.   

Abstract

Anti-neutrophil cytoplasm antibodies (ANCA) occur occasionally in rheumatoid arthritis (RA), but their incidence and clinical significance have been unclear. In this study we have investigated 58 patients with RA. In 22 patients the disease was inactive and the remaining 36 with active disease were further subdivided into those without clinical evidence of vasculitis (26), those with cutaneous vasculitis (8) and those with systemic vasculitis (2). ANCA were demonstrated by indirect immunofluorescence in 10 of the 58 patients (17%). While both perinuclear (pANCA) and cytoplasmic (cANCA) staining were detected, pANCA were more common (70%). Neutrophil-specific anti-nuclear antibodies (ANNA) were demonstrated in a further eight sera (14%) and ANA were detected on Hep-2 cells in 30 of the 58 sera (52%). ELISAs for the detection of anti-myeloperoxidase and anti-elastase antibodies were then established. Five sera with pANCA and five that contained ANNA were negative for both anti-myeloperoxidase and anti-elastase antibodies, suggesting other as yet unidentified cytoplasmic antigens as the target molecules. However, anti-myeloperoxidase or anti-elastase antibodies were found in four sera that had homogeneous or speckled ANA on both Hep-2 cells and neutrophils. One serum contained both antibodies. The presence of ANCA detected by indirect immunofluorescence or of anti-myeloperoxidase or anti-elastase antibodies in these patients with RA was not associated with disease activity nor with the demonstration of cutaneous vasculitis or renal disease (P NS). A possible association with systemic vasculitis remains to be confirmed. There is an incomplete correlation between indirect immunofluorescence patterns and antibody specificity in ELISA systems.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655318      PMCID: PMC1554154          DOI: 10.1111/j.1365-2249.1991.tb05779.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Anti-neutrophil cytoplasmic antibodies associated with atrial myxoma.

Authors:  J A Savige; S P Yeung; D J Davies; P Ebeling; D H Hunt
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

2.  On the incidence of antinuclear factors in rheumatoid arthritis. A comparative study, with special reference to the reaction with polymorphonuclear granulocytes.

Authors:  P Elling
Journal:  Acta Rheumatol Scand       Date:  1967

3.  Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis.

Authors:  C O Savage; C G Winearls; S Jones; P D Marshall; C M Lockwood
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

4.  Cutaneous vessel immune deposits in rheumatoid arthritis.

Authors:  D L Conn; A L Schroeter; F C McDuffie
Journal:  Arthritis Rheum       Date:  1976 Jan-Feb

5.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

6.  Antiperinuclear factor, a rheumatoid arthritis specific autoantibody: its relation to Epstein-Barr virus.

Authors:  A A Westgeest; A M van Loon; J T van der Logt; L B van de Putte; A M Boerbooms
Journal:  J Rheumatol       Date:  1989-05       Impact factor: 4.666

7.  An ultrastructural study of the pathogenesis of tissue injury in limited Wegener's granulomatosis.

Authors:  K J Donald; R L Edwards; J D McEvoy
Journal:  Pathology       Date:  1976-04       Impact factor: 5.306

8.  Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.

Authors:  F J van der Woude; N Rasmussen; S Lobatto; A Wiik; H Permin; L A van Es; M van der Giessen; G K van der Hem; T H The
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

9.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

Authors:  R J Falk; J C Jennette
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

10.  Diverse target antigens recognized by circulating antibodies in anti-neutrophil cytoplasm antibody-associated renal vasculitides.

Authors:  J A Savige; M Gallicchio; T Georgiou; D J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

View more
  16 in total

1.  Amphipathic variable region heavy chain peptides derived from monoclonal human Wegener's anti-PR3 antibodies stimulate lymphocytes from patients with Wegener's granulomatosis and microscopic polyangiitis.

Authors:  E Peen; C Malone; C Myers; R C Williams; A B Peck; E Csernok; W L Gross; R Staud
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

2.  Comparative effects of antilactoferrin antibodies and tumor necrosis factor on neutrophil adherence to matrix proteins.

Authors:  B Zweiman; C von Allmen
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations.

Authors:  Irena Manolova; Maria Dantcheva
Journal:  Rheumatol Int       Date:  2004-11-11       Impact factor: 2.631

4.  Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis.

Authors:  L Vasiliauskiene; A Wiik; M Høier-Madsen
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

5.  Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study.

Authors:  E Röther; T Schochat; H H Peter
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

6.  Clinical implications of ANCA positivity in a hospital setting: a tertiary center experience.

Authors:  Bashar Fteiha; Alon Bnaya; Marwan Abu Sneineh; Gideon Nesher; Gabriel Simon Breuer
Journal:  Intern Emerg Med       Date:  2020-10-06       Impact factor: 3.397

7.  Anti-neutrophil cytoplasm antibodies (ANCA) in rheumatoid arthritis: relationship to HLA-DR phenotypes, rheumatoid factor, anti-nuclear antibodies and disease severity.

Authors:  E Röther; D Metzger; B Lang; I Melchers; H H Peter
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

8.  Serological profile of rheumatoid arthritis in west Africa.

Authors:  A O Adebajo; P J Charles; B L Hazleman; R N Maini
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

9.  Anti-proteinase 3 antibodies, their characterization and disease associations.

Authors:  J G Jennings; L Chang; J A Savige
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

Review 10.  Mechanisms of endothelial cell injury in vasculitis.

Authors:  A A Pall; C O Savage
Journal:  Springer Semin Immunopathol       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.